-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cryo-Cell International, Inc. (OTCMKTS:CCEL) CEO David Portnoy Purchases 20,000 Shares
Cryo-Cell International, Inc. (OTCMKTS:CCEL) CEO David Portnoy Purchases 20,000 Shares
Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) CEO David Portnoy bought 20,000 shares of the company's stock in a transaction that occurred on Tuesday, November 8th. The stock was purchased at an average cost of $4.89 per share, for a total transaction of $97,800.00. Following the transaction, the chief executive officer now owns 204,080 shares in the company, valued at approximately $997,951.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
David Portnoy also recently made the following trade(s):
Get Cryo-Cell International alerts:- On Thursday, November 10th, David Portnoy acquired 3,850 shares of Cryo-Cell International stock. The stock was acquired at an average price of $4.90 per share, for a total transaction of $18,865.00.
Cryo-Cell International Stock Up 3.8 %
CCEL stock opened at $4.95 on Friday. Cryo-Cell International, Inc. has a twelve month low of $4.68 and a twelve month high of $14.00. The company has a market cap of $42.17 million, a price-to-earnings ratio of 33.00 and a beta of 0.35. The business has a 50 day moving average price of $5.83 and a two-hundred day moving average price of $5.96.
Cryo-Cell International (OTCMKTS:CCEL – Get Rating) last released its quarterly earnings data on Friday, October 14th. The company reported $0.06 earnings per share for the quarter. Cryo-Cell International had a net margin of 4.34% and a return on equity of 49.62%. The company had revenue of $7.70 million for the quarter.Cryo-Cell International Dividend Announcement
The firm also recently declared a dividend, which was paid on Friday, September 9th. Shareholders of record on Friday, September 2nd were issued a dividend of $0.90 per share. The ex-dividend date of this dividend was Thursday, September 1st.
Hedge Funds Weigh In On Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV grew its position in shares of Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,135 shares of the company's stock after buying an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned approximately 1.47% of Cryo-Cell International worth $732,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.01% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Maxim Group initiated coverage on shares of Cryo-Cell International in a research report on Monday, August 29th. They issued a "buy" rating and a $12.00 target price for the company.
Cryo-Cell International Company Profile
(Get Rating)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) CEO David Portnoy bought 20,000 shares of the company's stock in a transaction that occurred on Tuesday, November 8th. The stock was purchased at an average cost of $4.89 per share, for a total transaction of $97,800.00. Following the transaction, the chief executive officer now owns 204,080 shares in the company, valued at approximately $997,951.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
冷凍細胞國際公司首席執行官David·波特諾伊在11月8日星期二的一筆交易中購買了20,000股該公司股票。這隻股票是以每股4.89美元的平均價格購買的,總交易額為97,800.00美元。交易完成後,這位首席執行官現在擁有該公司204,080股股票,價值約997,951.20美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過此超鏈接.
David Portnoy also recently made the following trade(s):
David·波特諾伊最近還進行了以下交易:
- On Thursday, November 10th, David Portnoy acquired 3,850 shares of Cryo-Cell International stock. The stock was acquired at an average price of $4.90 per share, for a total transaction of $18,865.00.
- 11月10日,星期四,David·波特諾伊收購了3,850股冷凍細胞國際股票。股票是以每股4.90美元的平均價格收購的,總交易額為18865.00美元。
Cryo-Cell International Stock Up 3.8 %
低温細胞國際股價上漲3.8%
CCEL stock opened at $4.95 on Friday. Cryo-Cell International, Inc. has a twelve month low of $4.68 and a twelve month high of $14.00. The company has a market cap of $42.17 million, a price-to-earnings ratio of 33.00 and a beta of 0.35. The business has a 50 day moving average price of $5.83 and a two-hundred day moving average price of $5.96.
CCEL股票上週五開盤報4.95美元。Cryo-Cell International,Inc.的股價為4.68美元的12個月低點和14.00美元的12個月高位。該公司市值為4,217萬美元,市盈率為33.00倍,貝塔係數為0.35。該業務的50日移動均線價格為5.83美元,200日移動均線價格為5.96美元。
Cryo-Cell International Dividend Announcement
低温細胞國際分紅公告
The firm also recently declared a dividend, which was paid on Friday, September 9th. Shareholders of record on Friday, September 2nd were issued a dividend of $0.90 per share. The ex-dividend date of this dividend was Thursday, September 1st.
該公司最近還宣佈了股息,股息於9月9日星期五支付。9月2日星期五登記在冊的股東獲得了每股0.90美元的股息。本次股息除息日期為9月1日星期四。
Hedge Funds Weigh In On Cryo-Cell International
對衝基金看好Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV grew its position in shares of Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,135 shares of the company's stock after buying an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned approximately 1.47% of Cryo-Cell International worth $732,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.01% of the company's stock.
一家對衝基金最近增持了Cryo-Cell International股票。根據最近提交給美國證券交易委員會(SEC)的文件,麻省互惠信託公司FSB ADV在第二季度將其在Cryo-Cell International,Inc.(場外交易市場代碼:CCEL-GET評級)的股票頭寸增加了63.3%。在此期間,該公司又購買了48,100股,持有124,135股公司股票。截至最近一個季度末,MassMutual Trust Co.FSB ADV擁有Cryo-Cell International約1.47%的股份,價值73.2萬美元。機構投資者和對衝基金持有該公司9.01%的股票。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, Maxim Group initiated coverage on shares of Cryo-Cell International in a research report on Monday, August 29th. They issued a "buy" rating and a $12.00 target price for the company.
另外,Maxim Group在8月29日星期一的一份研究報告中啟動了對Cryo-Cell International股票的報道。他們對該公司的評級為“買入”,目標價為12美元。
Cryo-Cell International Company Profile
低温細胞國際公司簡介
(Get Rating)
(獲取評級)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.
國際冷凍細胞公司從事細胞處理和低温細胞存儲,專注於收集和保存供家庭使用的臍帶血幹細胞。它提供臍帶組織服務,存儲部分臍帶組織,臍帶組織是間充質幹細胞的來源,用於再生醫學,用於治療一系列疾病,包括心臟、腎臟疾病、肌萎縮側索硬化症、傷口癒合和自身免疫性疾病。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- 免費獲取StockNews.com關於低温細胞國際(CCEL)的研究報告
- 油價是股市拋售尚未結束的一個令人信服的原因
- 中盤Neurocrine生物科學是井噴後的第三季度報告嗎?
- 六面旗幟是一種你不想被困住的旅程
- 願景氫,現在的願景能源,將希望寄託在股票拆分上
- Hanesbrand可能發出零售類股本週表現不佳的信號
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
接受《冷凍細胞國際日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cryo-Cell International和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧